首頁 > 市場調查報告書 > 醫療設備

體外診斷癌症

歐洲肺癌篩檢市場預測至 2030 年 - 區域分析 - 按癌症類型、技術、年齡層（50 歲及以上和 50 歲以下）和最終用戶（醫院、診斷中心等）

市場調查報告書

商品編碼

1402526

歐洲肺癌篩檢市場預測至 2030 年 - 區域分析 - 按癌症類型、技術、年齡層（50 歲及以上和 50 歲以下）和最終用戶（醫院、診斷中心等）

Europe Lung Cancer Screening Market Forecast to 2030 - Regional Analysis - by Cancer Type, Technology, Age Group (50 & Older and Below 50), and End User (Hospitals, Diagnostic Centers, and Others)

出版日期: 2023年11月01日 | 出版商:

The Insight Partners | 英文 131 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

歐洲肺癌篩檢市場預計將從2022年的5.9325億美元成長到2030年的10.9099億美元。預計2022年至2030年CAGR為7.9%。

肺癌發生率上升推動了歐洲肺癌篩檢市場。

肺癌是全世界死亡的主要原因之一。肺癌篩檢是癌症預防方法的重要組成部分。肺癌患者的預後在早期診斷時會更好，因此肺癌高風險族群應進行常規檢查，以發現肺部癌性生長的形成。

根據癌症雜誌《腫瘤學年鑑》進行的研究，預計 2023 年歐盟地區將有約 1,261,990 名癌症患者死亡。肺癌死亡率將增加 1% 以上，達到每 10 萬人 13.6 人。由於越來越多的英國女性比歐盟女性更早開始吸菸，英國女性肺癌死亡率將下降 13.8%，儘管每 10 萬人中 16.2 人的死亡率仍高於歐盟女性。在英國，目前每 10 萬人中肺癌患者的死亡人數高於乳癌（每 10 萬人中 13.5 人）。

當研究人員特別檢查了英國以外的五個歐盟國家的肺癌死亡率時，他們發現，雖然人口最多的六個國家（法國、德國、義大利、波蘭和西班牙）的男性肺癌死亡率預計會下降，但他們發現，法國、義大利和西班牙的女性將分別增加約 14%、5.6% 和 5%。研究人員發現，在不同年齡層的女性中，25歲至64歲之間的肺癌預期死亡率有所下降，但65歲至75歲以上的女性肺癌預期死亡率上升，導致整體上升。此外，根據美國國家生物技術資訊中心 (NCBI) 的數據，義大利每年約有 41,000 例新診斷肺癌和 34,000 例死亡。因此，全球肺癌發生率的上升推動了肺癌篩檢計畫的啟動，這反過來又推動了市場的成長。

歐洲肺癌篩檢市場概況

歐洲肺癌篩檢市場分為德國、英國、法國、義大利、西班牙和歐洲其他地區。該地區的成長歸因於多種因素，例如肺癌發病率的增加以及人們對側肺癌篩檢和診斷的認知。此外，政府對篩檢的支持不斷增加，導致市場進一步成長。

肺癌盛行率的不斷增加使得篩檢對於早期發現變得極為重要。建議長期吸菸且沒有任何肺癌相關症狀的老年人進行肺癌篩檢。醫生使用低劑量電腦斷層掃描 (LDCT) 掃描或 X 光進行篩檢。

根據《胸腔腫瘤學雜誌》2022年6月發表的題為《德國肺癌》的文章，癌症是德國第二大常見死因之一，佔所有死亡的25%。在男性中，肺癌排名第二位，僅次於心血管疾病，佔全因死亡率的 6.5%。肺癌的年齡標化發生率男性和女性分別為52.1和32.7（每10萬人），在男性中排名第二，在女性中排名第三（分別佔所有新診斷癌症的13.3%和9.4%）。癌症診斷的平均年齡為70歲（男性）和69歲（女性）； 52% 的患者處於 IV 期。由於吸煙習慣的長期變化，自 20 世紀 90 年代以來，女性和男性的發病率趨同。目前，德國有四分之一的男性 (27.0%) 和五分之一的女性 (20.8%) 經常吸煙

歐洲肺癌篩檢市場收入及 2030 年預測（百萬美元）

歐洲肺癌篩檢市場細分

歐洲肺癌篩檢市場按癌症類型、技術、年齡層、最終用戶和國家細分。

根據癌症類型，歐洲肺癌篩檢市場分為非小細胞肺癌（NSCLC）和小細胞肺癌。 2022 年，非小細胞肺癌 (NSCLC) 細分市場在歐洲肺癌篩檢市場中佔據更大佔有率。

根據技術，歐洲肺癌篩檢市場分為胸部X光檢查、低劑量電腦斷層掃描（LDCT）、液體切片等。 2022 年，低劑量電腦斷層掃描 (LDCT) 領域在歐洲肺癌篩檢市場中佔據最大佔有率。

根據年齡層，歐洲肺癌篩檢市場分為50歲及以上及50歲以下。2022年，50歲及以上細分市場在歐洲肺癌篩檢市場中佔有較大佔有率。

根據最終用戶，歐洲肺癌篩檢市場分為醫院、診斷中心等。 2022年，醫院細分市場在歐洲肺癌篩檢市場中佔據最大佔有率。

根據國家/地區，歐洲肺癌篩檢市場分為德國、英國、法國、義大利、西班牙和歐洲其他地區。 2022年，德國在歐洲肺癌篩檢市場佔據主導地位。

西門子股份公司、荷蘭皇家飛利浦公司、佳能公司、美敦力公司、GE HealthCare、Nuance Communications Inc 和 Intelerad Medical Systems 是歐洲肺癌篩檢市場上的一些領先公司。

Lung cancer is among one of the main causes of mortality across the world. Lung cancer screening is a critical component of cancer prevention approaches. The prognosis of lung cancer patients is better when the disease is diagnosed early, so people at high risk of lung cancer are prompted to undergo routine checkups to detect the formation of cancerous growth in their lungs.

As per research conducted by the cancer journal Annals of Oncology, around 1,261,990 cancer patients are expected to die in 2023 in the EU region. Lung cancer death rates would increase by over 1% to 13.6 per 100,000. As more UK women started smoking earlier than those in the EU, there will be a 13.8% decrease in the death rate from lung cancer among women in the UK, although the death rate of 16.2 per 100,000 is still higher than among women in the EU. In the UK, lung cancer currently claims more per 100,000 than breast cancer, which claims 13.5 per 100,000.

When the researchers particularly examined lung cancer death rates in five EU nations in addition to the UK, they discovered that while rates are expected to decline for men in the most populous six nations (France, Germany, Italy, Poland, and Spain), they will increase for women in France, Italy, and Spain by about 14%, 5.6%, and 5%, respectively. The researchers discovered that among women in various age groups, expected mortality rates from lung cancer decreased among those between the ages of 25 and 64 but increased among those between the ages of 65 and over 75, leading to an increase overall. Also, according to the National Center for Biotechnology Information (NCBI), each year, ~41,000 new diagnoses of lung cancers and 34,000 deaths are recorded in Italy. Thus, the rising incidence of lung cancer worldwide is contributing to the initiation of lung cancer screening programs, which is, in turn, driving the market growth.

Europe Lung Cancer Screening Market Overview

The Europe lung cancer screening market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The regional growth is attributed to various factors, such as the increasing incidence of lung cancer and awareness of side lung cancer screening and diagnosis among people. Also, rising government support for screening has led to the further growth of the market.

The increasing prevalence of lung cancer has made its screening extremely important for early detection. Lung cancer screening is suggested for older adults who are long-time smokers and do not have any symptoms related to lung cancer. Physicians use a low-dose computerized tomography (LDCT) scan or X-ray for screening.

According to an article titled "Lung Cancer in Germany," published in the Journal of Thoracic Oncology, in June 2022, cancer is among the second most frequent cause of death in Germany, accounting for 25% of all deaths. In men, lung cancer ranks second after cardiovascular disease, accounting for 6.5% of all-cause mortality. With an age-standardized incidence rate of 52.1 and 32.7 and (per 100,000) in men and women, respectively, lung cancer ranks second in men and third in women (accounting for 13.3% and 9.4% of all newly diagnosed cancers, respectively). The average age of cancer diagnosis is 70 years (men) and 69 years (women); 52% of all patients present with stage IV. The incidence rates in women and men have converged since the 1990s because of long-term changes in smoking habits. Currently, every fourth man (27.0%) and every fifth woman (20.8%) in Germany smokes regularly

Europe Lung Cancer Screening Market Revenue and Forecast to 2030 (US$ Million)

Europe Lung Cancer Screening Market Segmentation

The Europe lung cancer screening market is segmented into cancer type, technology, age group, end user, and country.

Based on cancer type, the Europe lung cancer screening market is segmented into non-small cell lung cancer (NSCLC), and small cell lung cancer. The non-small cell lung cancer (NSCLC) segment held a larger share of the Europe lung cancer screening market in 2022.

Based on technology, the Europe lung cancer screening market is segmented into chest X-ray, low dose computed tomography (LDCT), liquid biopsy, and others. Low dose computed tomography (LDCT) segment held the largest share of the Europe lung cancer screening market in 2022.

Based on age group, the Europe lung cancer screening market is segmented into 50 and older, and below 50. 50 and older segment held the larger share of the Europe lung cancer screening market in 2022.

Based on end user, the Europe lung cancer screening market is segmented into hospital, diagnostic centre, and others. Hospital segment held the largest share of the Europe lung cancer screening market in 2022.

Based on country, the Europe lung cancer screening market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe lung cancer screening market in 2022.

Siemens AG, Koninklijke Philips NV, Canon Inc, Medtronic, GE HealthCare, Nuance Communications Inc, and Intelerad Medical Systems are some of the leading companies operating in the Europe lung cancer screening market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe Lung Cancer Screening Market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in Europe Lung Cancer Screening Market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Europe Market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

1. Introduction

1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 Europe Lung Cancer Screening Market - by Technology
- 1.3.2 Europe Lung Cancer Screening Market - by Cancer Type
- 1.3.3 Europe Lung Cancer Screening Market - by Age Group
- 1.3.4 Europe Lung Cancer Screening Market - by End User
- 1.3.5 Europe Lung Cancer Screening Market - by Country

2. Europe Lung Cancer Screening Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Lung Cancer Screening Market - Market Landscape

4.1 Overview
4.2 Europe PEST Analysis
4.3 Expert's Opinion

5. Europe Lung Cancer Screening Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Rising Lung Cancer Incidences
5.2 Market Restraints
- 5.2.1 High Cost of Lung Cancer Screening Tests
5.3 Market Opportunities
- 5.3.1 Structured Lung Cancer Screening Program
5.4 Future Trends
- 5.4.1 Mobile Lung Cancer Screening Truck
5.5 Impact Analysis

6. Europe Lung Cancer Screening Market - Europe Analysis

6.1 Europe Lung Cancer Screening Market Revenue Forecast and Analysis

7. Europe Lung Cancer Screening Market - Revenue and Forecast to 2028 - By Cancer Type

7.1 Overview
7.2 Europe Lung Cancer Screening Market Revenue Share, by Cancer Type 2022 & 2030 (%)
7.3 Non-Small Cell Lung Cancer (NSCLC)
- 7.3.1 Overview
- 7.3.2 Non-Small Cell Lung Cancer (NSCLC): Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Mn)
7.4 Small Cell Lung Cancer
- 7.4.1 Overview
- 7.4.2 Small Cell Lung Cancer: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Lung Cancer Screening Market Analysis - by Technology

8.1 Overview
8.2 Low-Dose Computed Tomography (LDCT)
- 8.2.1 Overview
- 8.2.2 Low-Dose Computed Tomography (LDCT): Europe Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
8.3 Chest X-ray
- 8.3.1 Overview
- 8.3.2 Chest X-ray: Europe Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
8.4 Liquid Biopsy
- 8.4.1 Overview
- 8.4.2 Liquid Biopsy: Europe Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
8.5 Others
- 8.5.1 Overview
- 8.5.2 Others: Europe Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)

9. Europe Lung Cancer Screening Market Analysis - by Age Group

9.1 Overview
9.2 & Older
- 9.2.1 Overview
- 9.2.2 & Older: Australia Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Below 50
- 9.3.1 Overview
- 9.3.2 Below 50: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)

10. Europe Lung Cancer Screening Market Analysis - by End User

10.1 Overview
10.2 Hospitals
- 10.2.1 Overview
- 10.2.2 Hospitals: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
10.3 Diagnostic Centers
- 10.3.1 Overview
- 10.3.2 Diagnostic Centers: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
10.4 Others
- 10.4.1 Overview
- 10.4.2 Others: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)

11. Europe Lung Cancer Screening Market - Revenue and Forecast to 2028 - Country Analysis

11.1 Europe: Europe Lung Cancer Screening Market Overview

12. Europe Lung Cancer Screening Market-Industry Landscape

12.1 Recent Growth Strategies
- 12.1.1 Overview

13. Company Profiles

13.1 Intelerad Medical Systems
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Nuance Communications Inc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 GE HealthCare
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Medtronic
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Canon Inc.
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Koninklijke Philips NV
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Siemens AG
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments

14. Appendix

14.1 About The Insight Partners
14.2 Glossary of Terms

簡介目錄圖表

List Of Tables

List of Tables

Table 1. Germany Europe Lung Cancer Screening Market, by Cancer Type - Revenue and Forecast to 20228 (US$ Million)
Table 2. Germany Europe Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
Table 3. Germany Europe Lung Cancer Screening Market, by Age Group - Revenue and Forecast to 2030 (US$ Million)
Table 4. Germany Europe Lung Cancer Screening Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 5. UK Europe Lung Cancer Screening Market, by Cancer Type - Revenue and Forecast to 20228 (US$ Million)
Table 6. UK Europe Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
Table 7. UK Europe Lung Cancer Screening Market, by Age Group - Revenue and Forecast to 2030 (US$ Million)
Table 8. UK Europe Lung Cancer Screening Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 9. France Europe Lung Cancer Screening Market, by Cancer Type - Revenue and Forecast to 20228 (US$ Million)
Table 10. France Europe Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
Table 11. France Europe Lung Cancer Screening Market, by Age Group - Revenue and Forecast to 2030 (US$ Million)
Table 12. France Europe Lung Cancer Screening Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 13. Italy Europe Lung Cancer Screening Market, by Cancer Type - Revenue and Forecast to 20228 (US$ Million)
Table 14. Italy Europe Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
Table 15. Italy Europe Lung Cancer Screening Market, by Age Group - Revenue and Forecast to 2030 (US$ Million)
Table 16. Italy Europe Lung Cancer Screening Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 17. Spain Europe Lung Cancer Screening Market, by Cancer Type - Revenue and Forecast to 20228 (US$ Million)
Table 18. Spain Europe Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
Table 19. Spain Europe Lung Cancer Screening Market, by Age Group - Revenue and Forecast to 2030 (US$ Million)
Table 20. Spain Europe Lung Cancer Screening Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 21. Rest of Europe Lung Cancer Screening Market, by Cancer Type - Revenue and Forecast to 20228 (US$ Million)
Table 22. Rest of Europe Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
Table 23. Rest of Europe Lung Cancer Screening Market, by Age Group - Revenue and Forecast to 2030 (US$ Million)
Table 24. Rest of Europe Lung Cancer Screening Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 25. Recent Growth Strategies in the Europe Lung Cancer Screening Market
Table 26. Glossary of Terms

List Of Figures

List of Figures

Figure 1. Europe Lung Cancer Screening Market Segmentation
Figure 2. Europe Lung Cancer Screening Market, by Country
Figure 3. Europe Lung Cancer Screening Market Overview
Figure 4. Non-Small Cell Lung Cancer Segment Held Largest Share of Cancer Type Segment in Europe Lung Cancer Screening Market
Figure 5. Asia Pacific Expected to Show Remarkable Growth During Forecast Period
Figure 6. Europe: PEST Analysis
Figure 7. Experts' Opinion
Figure 8. Europe Lung Cancer Screening Market Impact Analysis of Driver and Restraints
Figure 9. Europe Lung Cancer Screening Market - Revenue Forecast and Analysis - 2020-2030
Figure 10. Europe Lung Cancer Screening Market Revenue Share, by Cancer Type 2022 & 2030 (%)
Figure 11. Non-Small Cell Lung Cancer (NSCLC): Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Small Cell Lung Cancer: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Europe Lung Cancer Screening Market, by Technology, 2022 & 2030 (%)
Figure 14. Low-Dose Computed Tomography (LDCT): Europe Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
Figure 15. Chest X-ray: Europe Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
Figure 16. Liquid Biopsy: Europe Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
Figure 17. Others: Europe Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
Figure 18. Europe Lung Cancer Screening Market, by Age group, 2022 & 2030 (%)
Figure 19. & Older: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Below 50: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Europe Lung Cancer Screening Market, by End User, 2022 & 2030 (%)
Figure 22. Hospitals: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Diagnostic Centers: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. Europe Lung Cancer Screening Market, by Key Country - Revenue (2022) (US$ Million)
Figure 26. Europe Lung Cancer Screening Market Revenue Share, by Country, (2022 & 2030)
Figure 27. Germany: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
Figure 28. UK: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
Figure 29. France: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
Figure 30. Italy: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
Figure 31. Spain: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
Figure 32. Rest of Europe: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)